News & Blog

Widely-available Drug May Benefit Glioblastoma Treatment

Based on data from NBTS’s Defeat GBM Research Collaborative and with support from the Sharpe family, Dr. Paul Mischel (Stanford University) and his laboratory team found that the antidepressant drug, fluoxetine (common brand name: Prozac), potently targets tumor metabolism and inhibits epidermal growth factor (EGFR) signaling, triggering the killing of glioblastoma (GBM) cells. Dr. Mischel’s […]

Years of scientific progress lead to hope for glioblastoma patient

With funding from the National Brain Tumor Society, Clark C. Chen, MD, PhD of the University of Minnesota is ready to start a clinical trial for a drug that is already showing early promise for a glioblastoma patient. The following blog, which has been lightly edited, was originally published on the University of Minnesota’s Neurosurgery […]

Advocacy in Action: Updates on the Childhood Cancer STAR Act and Childhood Cancer Data Initiative

The Childhood Cancer STAR Act and Childhood Cancer Data Initiative (CCDI) are major federal government-led initiatives that exist in part because of years of advocacy work by members of the brain tumor and childhood cancer communities. As we reflect back on Childhood Cancer Awareness Month (CCAM) this past September, we want to share updates on […]

Share